Home
January 2010 February 2010 March 2010
Su Mo Tu We Th Fr Sa
Week 5 1 2 3 4 5 6
Week 6 7 8 9 10 11 12 13
Week 7 14 15 16 17 18 19 20
Week 8 21 22 23 24 25 26 27
Week 9 28
Reach urologists

Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency - Abstract Show Comments PDF Print E-mail
  
Monday, 30 November 2009

Department of Urology, Centre for Applied Urological Research, Queen's University, Kingston, Ontario, Canada.

This email address is being protected from spam bots, you need Javascript enabled to view it

Supplemental administration of androgens has been advocated for men with sexual dysfunction (SD) and hypoandrogenism. The preponderance of evidence indicates that most delivery forms of testosterone (T) are effective but the role of dehydroepiandrosterone (DHEA) is controversial. A placebo-controlled, randomized trial of oral androgen (T versus DHEA) supplementation was carried out to determine their efficacy.

Eighty-six men with SD and decreased levels of serum T and/or DHEA, participated in a study receiving oral T undecanoate (OTU) (n = 29) 80 mg twice daily, DHEA (n = 28) 50 mg twice daily, or placebo (n = 29). Outcomes included evaluation of sexual performance by the International Index of Erectile Function (IIEF), the Androgen Deficiency in the Aging Male (ADAM), Aging Male Symtom Scale (AMS), and Global Assessment Questionnaire (GAQ) questionnaires. Biochemical evaluations included measurement of T and DHEA, prolactin, gonadotropins, and PSA.

Seventy-nine men completed the study. There were no significant differences in outcomes as assessed by four different instruments: the ADAM, IIEF, AMS, and GAQ in regard to sexual interest or erectile function. Biochemically, a significant increase in serum DHEA between baseline and final visit was documented in the group receiving DHEA. The levels of T, on the other hand, increased insignificantly between entry and final visit in the T cohort. No biochemical changes were observed in the placebo group. Levels of PSA remained stable in all three groups.

This study did not suggest a clinical benefit of OTU or DHEA supplementation in men with hypoandrogenism and SD. The recommended dose of OTU may have been inadequate or poorly absorbed. Increased doses or an alternative T delivery form may result in a different response.

Written by:
Morales A, Black A, Emerson L, Barkin J, Kuzmarov I, Day A.   Are you the author?

Reference:
Aging Male. 2009 Dec;12(4):104-12.

PubMed Abstract
PMID:19883295

UroToday.com Androgen Deficiency Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 4
PoorBest


 
Visitor Ratings:
Healthcare Professionals:
3 (3 votes)

Patients:
4 (1 votes)


Bookmark and Share

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts



Featured Conference

Media and Publisher

Advertising Rates

Working with Industry

Case Studies
Sponsorship Opportunities